Conjugation of methotrexate onto dedoped Fe3O4/PPy nanospheres to produce magnetic targeting drug with controlled drug release and targeting specificity for HeLa cells

Jiang, Haihui; Zhao, Lichun; Gai, Ligang; Wang, Yang; Hou, Yanjin; Liu, Hong

doi:10.1016/j.synthmet.2015.06.006

Cited by 20 publications

(8 citation statements)

References 48 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reflection peaks at 30.1 ∘ , 35.4 ∘ , 43.1 ∘ , 53.5 ∘ , 56.9 ∘ , and 62.5 ∘ can be assigned to (220), (311), (400), (422), (511), and (440) crystal planes of cubic magnetite [27]. It can be concluded that the magnetite-GO heterostructure was formed.…”

Section: Xrd Analysis As Exhibited Inmentioning

confidence: 91%

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Zhang

Wen-bin

et al. 2017

Journal of Nanomaterials

View full text Add to dashboard Cite

The Fe 3 O 4 /reduced graphene oxide (Fe 3 O 4 /RGO) nanocomposites with good dispersibility were synthesized for targeted delivery of paclitaxel (PTX). Firstly, the superparamagnetic Fe 3 O 4 /functional GO nanocomposites were prepared via hydrothermal method in which GO sheets were modified by surfactant wrapping. The Fe 3 O 4 /RGO nanocomposites were successively prepared through the reduction of graphene oxide. The products were investigated by Fourier-transform infrared spectrum, X-ray diffraction, scanning electron microscopy, transmission electron microscopy, thermogravimetric analysis, and vibration sample magnetometry. It was found that spherical Fe 3 O 4 nanoparticles were uniformly anchored over the RGO matrix and the nanocomposites were superparamagnetic with saturation magnetization (Ms) of 9.39 emu/g. Then PTX was loaded onto Fe 3 O 4 /RGO nanocomposites, and the drug loading capacity was 67.9%. Cell viability experiments performed on MCF-7 demonstrated that the Fe 3 O 4 /RGOloaded PTX (Fe 3 O 4 /RGO/PTX) showed cytotoxicity to MCF-7, whereas the Fe 3 O 4 /RGO displayed no obvious cytotoxicity. The above results indicated that Fe 3 O 4 /RGO/PTX nanocomposites had potential application in tumor-targeted chemotherapy.

show abstract

Section: Xrd Analysis As Exhibited Inmentioning

confidence: 91%

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Zhang

Wen-bin

et al. 2017

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

“…In addition to folic acid, the analog methotrexate (MTX) targets the folate receptor, and also exhibits therapeutic effects for a range of cancer types. MTX has been conjugated to nanoparticles with the goal of targeting 62 and drug delivery. 63 The carboxyl groups of MTX were activated by a carbodiimide reaction with the coupling agent (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC), followed by NHS and subsequent reaction with the beads.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

“…The ligand exchange was carried out as previously reported with slight variations. 62 [Mn 3 (O 2 CCH 3 ) 6 (Pyr) 3 ] or Mn 3 Pyr (4). This cluster was synthesized as previously reported.…”

Section: ■ Conclusionmentioning

confidence: 99%

Paramagnetic Clusters of Mn₃(O₂CCH₃)₆(Bpy)₂ in Polyacrylamide Nanobeads as a New Design Approach to a T₁–T₂ Multimodal Magnetic Resonance Imaging Contrast Agent

Dahanayake¹,

Pornrungroj

Pablico-Lansigan

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

There is an increasing need for gadolinium-free magnetic resonance imaging (MRI) contrast agents, particularly for patients suffering from chronic kidney disease. Using a cluster−nanocarrier combination, we have identified a novel approach to the design of biomedical nanomaterials and report here the criteria for the cluster and the nanocarrier and the advantages of this combination. We have investigated the relaxivity of the following manganese oxo clusters: the parent cluster Mn 3 (O 2 CCH 3 ) 6 (Bpy) 2 (1) where Bpy = 2,2′-bipyridine and three new analogs, Mn 3 (O 2 CC 6 H 4 CHCH 2 ) 6 (Bpy) 2 (2), Mn 3 (O 2 CC(CH 3 )CH 2 ) 6 (Bpy) 2 (3), and Mn 3 O(O 2 CCH 3 ) 6 (Pyr) 2 (4) where Pyr = pyridine. The parent cluster, Mn 3 (O 2 CCH 3 ) 6 (Bpy) 2 (1), had impressive relaxivity (r 1 = 6.9 mM −1 s −1 , r 2 = 125 mM −1 s −1 ) and was found to be the most amenable for the synthesis of cluster-nanocarrier nanobeads. Using the inverse miniemulsion polymerization technique (1) in combination with the hydrophilic monomer acrylamide, we synthesized nanobeads (∼125 nm diameter) with homogeneously dispersed clusters within the polyacrylamide matrix (termed Mn 3 Bpy-PAm). The nanobeads were surfacemodified by co-polymerization with an amine-functionalized monomer. This enabled various postsynthetic modifications, for example, to attach a near-IR dye, Cyanine7, as well as a targeting agent. When evaluated as a potential multimodal MRI contrast agent, high relaxivity and contrast were observed with r 1 = 54.4 mM −1 s −1 and r 2 = 144 mM −1 s −1 , surpassing T 1 relaxivity of clinically used Gd-DTPA chelates as well as comparable T 2 relaxivity to iron oxide microspheres. Physicochemical properties, cellular uptake, and impacts on cell viability were also investigated.

show abstract

“…Therefore, controlling the size of Fe 3 O 4 magnetic nanoparticles through the solvothermal method is still a major challenge. Polypyrrole (PPy) has excellent electrical conductivity, stability, biocompatibility, and biodegradability, and the amino groups on the skeleton can provide the connection sites for the drug and connect hydrophobic drugs through π–π stacking action [ 27 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Monodisperse Fe3O4/SiO2 and Fe3O4/SiO2/PPy Core-Shell Composite Nanospheres for IBU Loading and Release

Shen

Qiao

et al. 2019

Materials

View full text Add to dashboard Cite

The magnetic targeting drug delivery system is an effective way of targeting therapy. In this study, the monodisperse Fe3O4 nanoparticles with a particles size of about 180 nm were first prepared via a solvothermal method. Subsequently, the core-shell structure Fe3O4/SiO2 and Fe3O4/SiO2/polypyrrole (PPy) composite nanospheres were successfully synthesized by coating Fe3O4 nanoparticles with SiO2 shell layer using the Stöber method and PPy shell by solvothermal method in turn. The as-prepared nanoparticles were characterized using transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier transform-infrared spectroscopy (FT-IR), vibrating sample magnetometer (VSM), thermogravimetric analysis (TGA), and Ultraviolet-Visible spectrophotometer (UV-Vis). The results indicated that the as-prepared composite nanospheres displayed a well-defined core-shell structure and monodispersity. The thicknesses of SiO2 shell and PPy shell were ~6 nm and ~19 nm, respectively. Additionally, the as-prepared nanoparticles exhibited high saturation magnetization of 104 emu/g, 77 emu/g, and 24 emu/g, and have great potential applications in drug delivery. The drug loading and drug release of the Fe3O4/SiO2 and Fe3O4/SiO2/PPy composite nanospheres to ibuprofen (IBU) under stirring and ultrasonication were investigated. Their drug loading efficiency and drug release efficiency under ultrasonication were all higher than 33% and 90%, respectively. The drug release analyses showed sustained release of IBU from nanospheres and followed the Korsmeyer-Peppas model.

show abstract

Conjugation of methotrexate onto dedoped Fe3O4/PPy nanospheres to produce magnetic targeting drug with controlled drug release and targeting specificity for HeLa cells

Cited by 20 publications

References 48 publications

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Paramagnetic Clusters of Mn₃(O₂CCH₃)₆(Bpy)₂ in Polyacrylamide Nanobeads as a New Design Approach to a T₁–T₂ Multimodal Magnetic Resonance Imaging Contrast Agent

Monodisperse Fe3O4/SiO2 and Fe3O4/SiO2/PPy Core-Shell Composite Nanospheres for IBU Loading and Release

Contact Info

Product

Resources

About

Conjugation of methotrexate onto dedoped Fe3O4/PPy nanospheres to produce magnetic targeting drug with controlled drug release and targeting specificity for HeLa cells

Cited by 20 publications

References 48 publications

Preparation of Fe3O4/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Preparation of Fe3O4/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Paramagnetic Clusters of Mn3(O2CCH3)6(Bpy)2 in Polyacrylamide Nanobeads as a New Design Approach to a T1–T2 Multimodal Magnetic Resonance Imaging Contrast Agent

Monodisperse Fe3O4/SiO2 and Fe3O4/SiO2/PPy Core-Shell Composite Nanospheres for IBU Loading and Release

Contact Info

Product

Resources

About

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Preparation of Fe₃O₄/Reduced Graphene Oxide Nanocomposites with Good Dispersibility for Delivery of Paclitaxel

Paramagnetic Clusters of Mn₃(O₂CCH₃)₆(Bpy)₂ in Polyacrylamide Nanobeads as a New Design Approach to a T₁–T₂ Multimodal Magnetic Resonance Imaging Contrast Agent